Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 7, 2013, Pages 814-819

  Wang, Jiu Ping ^a   Zhang, Ye ^a   Lian, Jian Qi ^a   Li, Yu ^b   Wang, Jie Pin ^a   Huang, Chang Xing ^a   Bai, Xue Fan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Adefovir; chronic hepatitis B; resistance; telbivudine; virological breakthrough

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GENE DOSAGE; GENOTYPING TECHNIQUE; HEPATITIS B; HUMAN; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENINE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; ORGANOPHOSPHONATES; PHENOTYPE; THYMIDINE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84879941311     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835ee516     Document Type: Article

References (28)

1. Lok AS, Mc Mahon BJ. Chronic hepatitis B. Hepatology 2001; 34:1225-1241.
2. Lok AS, Mc Mahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis Cvirus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.
5. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012; 56 (Suppl 1):S112-S122.
6. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007; 11:797-816, viii.
7. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26:628-638.
8. Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag 2009; 5:789-798.
9. Lok AS, Mc Mahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
10. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
11. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBe Ag-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
12. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBe Ag-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
13. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53:1854-1863.
14. Lui YY, Chan HL. A review of telbivudine for the management of chronic hepatitis B virus infection. Expert Opin Drug Metab Toxicol 2008; 4:1351-1361.
15. Lui YY, Chan HL. Treatment of chronic hepatitis B: focus on telbivudine. Expert Rev Anti Infect Ther 2009; 7:259-268.
16. Hartwell D, Jones J, Harris P, Cooper K. Telbivudineforthetreatmentofchronic hepatitis B infection. Health Technol Assess 2009; 13 (Suppl 3):23-30.
17. Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 2007; 29:2635-2653.
18. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136:486-495.
19. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47:447-454.
20. European Association For The Study Of The Liver. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
21. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien R-N, Liu CJ, et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6:531-561.
22. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46:254-265.
23. Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354:1807-1812.
24. Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiol 2008; 3:525-538.
25. Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis 2007; 11:869-892.
26. Lau GK. Current treatments for patients with HBe Ag-positive chronic hepatitis B virus infection: a comparison focusing on HBe Ag seroconversion. Liver Int 2010; 30:512-520.
27. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010; 55:2727-2734.
28. Mc Keage K, Keam SJ. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs 2010; 70:1857-1883. Development Program of China Program of China Program of China Program of China